The Treatment experience, burden, and unmet needs (TRIBUNE) study – measuring the socioeconomic consequences of Multiple Sclerosis-Reference-Cited by-同舟云学术

The Treatment experience, burden, and unmet needs (TRIBUNE) study – measuring the socioeconomic consequences of Multiple Sclerosis

Published:2012-05-23 Issue:2_suppl Volume:18 Page:5-6
ISSN:1352-4585
Container-title:Multiple Sclerosis Journal
language:en
Short-container-title:Mult Scler

Author:

Fattore Giovanni¹,Lang Michael²,Pugliatti Maura³

Affiliation:

1. PhD Department of Institutional Analysis and Public Management and Centre for Research in Healthcare Management (CERGAS) Universita’ BocconiVia Roentgen 1, 20136 Milan, Room 3C1-05

2. Nervenärztliche Gemeinschaftspraxis Dr(s) Lang, Schreiber, Krauss, Kornhuber, Kriebel Pfauengasse 8 89073 Ulm, Germany

3. Dip. di Medicina Clinica e Sperimentale – Neurologia Università degli Studi di Sassari Viale San Pietro 10 07100 Sassari, Italy,

Publisher

SAGE Publications

Subject

Neurology (clinical),Neurology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1352458512447262

Reference10 articles.

1. Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis

2. The Neurobiology of Multiple Sclerosis: Genes, Inflammation, and Neurodegeneration

3. Multiple sclerosis trait: the premorbid stage of multiple sclerosis. A hypothesis

4. The epidemiology of multiple sclerosis in Europe

5. European Charcot Foundation Lecture: The natural history of multiple sclerosis and gender

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adherence to subcutaneous interferon beta-1a treatment among patients with relapsing multiple sclerosis: the MAIN-MS study;Frontiers in Neurology;2023-11-28

2. Repetitive transcranial magnetic stimulation for treatment of limb spasticity following multiple sclerosis: a systematic review and meta-analysis;Brazilian Journal of Medical and Biological Research;2023

3. The impact of socioeconomic status on subsequent neurological outcomes in multiple sclerosis;Multiple Sclerosis and Related Disorders;2022-09

4. Evobrutinib, a covalent Bruton’s tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants;Clinical and Translational Science;2021-08-10

5. Economic burden of highly active relapsing-remitting multiple sclerosis patients in the French national health insurance database;Expert Review of Pharmacoeconomics & Outcomes Research;2021-07-08